Figure 4. Modulation of endogenous IL 17 and IL-23R by new RORγ inverse agonist probe (CID 51035449; ML310/SR2211) in EL-4 cells.

Figure 4Modulation of endogenous IL 17 and IL-23R by new RORγ inverse agonist probe (CID 51035449; ML310/SR2211) in EL-4 cells

Expression of endogenous IL 17A and IL-23R in EL-4 cells was reduced by treatment with ML310. EL-4 cells were pretreated with Digoxin (5 μM) or Probe ML310 (5 μM) or DMSO for 20 hours followed by stimulation with PMA and ionomycin for 5 hours. IL-17A (a) and IL-23R (b) mRNA expression was quantitated and normalized to GAPDH, or intracellular IL-17 protein (c) expression was measured. The results are shown as mean ± SEM; *p < 0.05, ***p < 0.0005.

From: Identification of a novel selective inverse agonist probe and analogs for the Retinoic acid receptor-related Orphan Receptor Gamma (RORγ)

Cover of Probe Reports from the NIH Molecular Libraries Program
Probe Reports from the NIH Molecular Libraries Program [Internet].

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.